Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | The CXCR4/CXCL12 axis as a potential therapeutic target in mycosis fungoides

Lilach Moyal • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, explains how the CXCR4/CXCL12 axis was identified as a potential new target to treat mycosis fungoides (MF). Analysis of the tumor microenvironment showed that stromal fibroblasts secreted high levels of the CXCL12 chemokine, which is a ligand binding CXCR4. This receptor was also found to be overexpressed in MF, prompting experiments using a CXCR4 inhibitor, which showed that inhibiting this axis led to selective killing of lymphoma cells. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Lilach Moyal

0:57
The effect of CXCR4 inhibition on malignant cells
Lilach Moyal • 15 Oct 2021
1:43
Potential clinical applications of CXCR4 antagonists in cancer
Lilach Moyal • 15 Oct 2021
0:47
Mechanism of CXCR4 inhibition
Lilach Moyal • 15 Oct 2021
0:58
Next steps in the development of CXCR4 inhibitors for mycosis fungoides
Lilach Moyal • 15 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals